This technology identifies Bruton's Tyrosine Kinase (BTK) as a novel target in breast cancer therapy and provides methods for treatment and diagnosis by inhibiting a specific BTK variant.
Background: Protein tyrosine kinases (PTKs) are essential enzymes involved in cellular communication and regulation, often playing a significant role in cancer development. Bruton's Tyrosine Kinase (BTK), traditionally known for its role in B cell development, has been found to be critical for the survival of certain breast cancer cells. Research revealed that breast tumor cells express a variant form of BTK at elevated levels compared to normal cells, establishing a new perspective on BTK’s function beyond the immune system and suggesting it as a potential therapeutic target in oncology.
Technology Overview: This technology centers on the discovery and exploitation of a specific variant of BTK with an amino-terminal extension that is predominantly expressed in breast cancer cells. Using RNA interference (RNAi) screening techniques, researchers identified that suppressing BTK expression leads to reduced survival of breast cancer cells. The technology includes methods for targeting this BTK variant with inhibitors, especially RNAi-based therapeutics, to selectively impair cancer cell growth. Furthermore, it proposes diagnostic strategies to detect the BTK variant as a biomarker for breast cancer, enabling more precise diagnosis and monitoring. The innovation lies in recognizing BTK’s critical role in tumor development outside its known immune function and providing tailored approaches for both treatment and detection by focusing on the variant uniquely upregulated in cancerous tissue. This dual therapeutic and diagnostic potential offers a promising avenue for improving breast cancer management.
https://suny.technologypublisher.com/files/sites/adobestock_837848980.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Target specificity: Focuses on a BTK variant uniquely elevated in breast cancer cells, allowing precise therapeutic targeting. • Dual functionality: Enables both treatment through BTK inhibition and diagnosis via detection of the BTK variant. • Innovative approach: Utilizes RNA interference technology for selective suppression of cancer cell proliferation. • Potential for improved outcomes: By directly targeting essential cancer cell survival pathways, it may lead to more effective therapies with fewer side effects. • Foundation for drug development: Offers a basis for creating novel BTK inhibitors tailored to breast cancer applications.
Applications: • Development of anti-cancer drugs aimed at inhibiting BTK activity in breast tumors. • Diagnostic tools for detecting the presence or levels of the BTK variant as a biomarker for breast cancer. • Personalized medicine approaches that use BTK variant status to guide treatment decisions. • Research applications in understanding cancer cell survival mechanisms related to tyrosine kinase signaling. • Potential expansion to other cancers where BTK variants may play a role in disease progression.
Intellectual Property Summary: Issued patent 8,513,212
Stage of Development: TRL 4
Licensing Status: This technology is available for licensing.